Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Prednisolone

FDA-approved product (tablet, oral), marketed as Cortalone, Delta-Cortef, Fernisolone-P and 4 more.

Registered studies
39
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Prednisolone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Allergic conjunctivitis
  • Allergic rhinitis
  • Ankylosing spondylitis
  • Aplastic anemia
  • Asthma
  • Atopic eczema
  • Chorioretinitis
  • Choroiditis
  • Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency
  • Contact dermatitis
  • Crohn's disease
  • Dermatitis herpetiformis
  • Dermatomyositis
  • Eosinophilic pneumonia
  • Epicondylitis
  • Erythema multiforme
  • and 42 more

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids for local oral treatment; Corticosteroids acting locally; Corticosteroids; Corticosteroids, weak (group i); Corticosteroids, weak, other combinations
FDA pharmacologic class
Corticosteroid FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli32.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae21.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis33.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

39registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Prednisolone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Prednisolone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Use of Collatamp G Antibiotic Impregnated Sponges in the Treatment of Peri-prosthetic Total Joint Infections

    NCT01667874 · start 2013-01

    Registered record
    Registry ID
    NCT01667874
    Conditions
    Infection
    Interventions
    Collatamp G sponge
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2013-01
    Completion
    2016-09-01
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection
    InterventionCollatamp G sponge
    PhasePhase 3
    Registry statusTerminated

  • Efficacy, Pharmacokinetics and Safety of Meropenem in Infants Below 90 Days With Clinical or Confirmed Late-onset Sepsis

    NCT01551394 · start 2012-09

    Registered record
    Registry ID
    NCT01551394
    Conditions
    Sepsis
    Interventions
    Meropenem; Ampicillin + gentamicin or cefotaxime + gentamicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-09
    Completion
    2014-12
    Enrolment
    272

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSepsis
    InterventionMeropenem; Ampicillin + gentamicin or cefotaxime + gentamicin
    PhasePhase 3
    Registry statusCompleted

  • Effectiveness of Polymyxin B Sulphate + Prednisolone + Benzocaine + Clioquinol in Acute and Sub-acute Dermatitis Eczematous

    NCT01429701 · start 2012-05

    Registered record
    Registry ID
    NCT01429701
    Conditions
    Eczema
    Interventions
    polymyxin B sulphate + prednisolone + benzocaine + clioquinol; betamethasone + gentamicin + tolnaftato + cleoquinol
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-05
    Completion
    2012-08
    Enrolment
    76

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEczema
    Interventionpolymyxin B sulphate + prednisolone + benzocaine + clioquinol; betamethasone + gentamicin + tolnaftato + cleoquinol
    PhasePhase 3
    Registry statusCompleted

  • Drug Delivery Devices for Osteomyelitis

    NCT02968693 · start 2011-04

    Registered record
    Registry ID
    NCT02968693
    Conditions
    Osteomyelitis
    Interventions
    antibiotic-loaded calcium sulfate; antibiotic-loaded polymethyl methacrylate; Vancomycin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2011-04
    Completion
    2016-07
    Enrolment
    51

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteomyelitis
    Interventionantibiotic-loaded calcium sulfate; antibiotic-loaded polymethyl methacrylate; Vancomycin
    PhaseNot recorded
    Registry statusCompleted

  • Clinical Trials to Reduce the Risk of Antimicrobial Resistance

    NCT01570192 · start 2010-09

    Registered record
    Registry ID
    NCT01570192
    Conditions
    Bacterial Pneumonia
    Interventions
    IV meropenem; I.V. Meropenem; Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h; amikacin sulfate injection USP 20 mg/kg IV q24h; Linezolid or Vancomycin (per institutional guidelines) will be available for MRSA coverage.; tobramycin nebulization
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2010-09
    Completion
    2015-04
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Pneumonia
    InterventionIV meropenem; I.V. Meropenem; Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h +3 more
    PhasePhase 2
    Registry statusTerminated

  • Safety and Efficacy of Quadriderme® in the Treatment of Impetiginous Eczema (Study P05134AM4)

    NCT00671528 · start 2009-07

    Registered record
    Registry ID
    NCT00671528
    Conditions
    Dermatitis, Atopic; Eczema, Atopic; Skin Diseases, Eczematous
    Interventions
    Cream (betamethasone diproprionate, clotrimazole, and gentamicin sulfate); Cream (betamethasone diproprionate and gentamicin); Cream (betamethasone diproprionate)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2009-07
    Completion
    2010-05
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDermatitis, Atopic; Eczema, Atopic; Skin Diseases, Eczematous
    InterventionCream (betamethasone diproprionate, clotrimazole, and gentamicin sulfate); Cream (betamethasone diproprionate and gentamicin); Cream (betamethasone diproprionate)
    PhasePhase 4
    Registry statusTerminated

  • A Study Evaluating the Role of Oral Antibiotics in an Aim to Eradicate Carrier State of Carbapenem- Resistant Klebsiella Pneumonia (KPC).

    NCT01266499 · start 2009-07

    Registered record
    Registry ID
    NCT01266499
    Conditions
    Klebsiella Pneumoniae Carbapenemase Resistant Associated Bacteremia or Pneumonia
    Interventions
    Colistin (Polymyxin E) 100mg x 4/d; both medications; will not receive PO treatment; PO Garamycin 80mg x 4/d
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2009-07
    Completion
    2012-01
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKlebsiella Pneumoniae Carbapenemase Resistant Associated Bacteremia or Pneumonia
    InterventionColistin (Polymyxin E) 100mg x 4/d; both medications; will not receive PO treatment; PO Garamycin 80mg x 4/d
    PhaseNot applicable
    Registry statusCompleted

  • A Study to Evaluate the Efficacy and Tolerance of WR279,396 for Old World Cutaneous Leishmaniasis

    NCT01536795 · start 2005-10

    Registered record
    Registry ID
    NCT01536795
    Conditions
    Old World Cutaneous Leishmaniasis
    Interventions
    WR279,396 with Tegaderm Dressing; WR 279,396 with Gauze and Tape Dressing
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-10
    Completion
    2007-02
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOld World Cutaneous Leishmaniasis
    InterventionWR279,396 with Tegaderm Dressing; WR 279,396 with Gauze and Tape Dressing
    PhasePhase 2
    Registry statusCompleted

  • Reduction of Bacterial Resistance With Inhaled Antibiotics in the Intensive Care Unit

    NCT01878643 · start 2001-12

    Registered record
    Registry ID
    NCT01878643
    Conditions
    Respiratory Infection; Bacterial Resistance; Respiratory Failure
    Interventions
    vancomycin or gentamicin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2001-12
    Completion
    2002-12
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRespiratory Infection; Bacterial Resistance; Respiratory Failure
    Interventionvancomycin or gentamicin; Placebo
    PhaseEarly phase 1
    Registry statusCompleted